Navigation Links
NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Date:12/14/2007

SOPHIA ANTIPOLIS, France, Dec. 14 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced it has successfully completed the enrollment of 1020 patients in the 302 pivotal phase 3 study for naproxcinod, in-line with projections. Naproxcinod is the Company's lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class. The 302 study is designed to assess naproxcinod's efficacy for treating the signs and symptoms of osteoarthritis and provide additional blood pressure data, which is a key factor for differentiating naproxcinod from existing anti-inflammatory treatments. Efficacy results from this study are anticipated in the third quarter of 2008.

The 302 study represents the largest of the three pivotal phase 3 trials for naproxcinod (the 301, 302 and 303 studies). The 301 study is complete and results were recently presented at the 71st annual meeting of the American College of Rheumatology (ACR), which showed that naproxcinod met all three co-primary efficacy endpoints and demonstrated a similar effect on systolic blood pressure to placebo and a reduction compared to naproxen, a commonly used anti-inflammatory agent. The third and final study (303) is a 13-week trial in patients with osteoarthritis of the hip. Patient enrollment in this trial is well underway, following its initiation in June 2007. Current timelines are that the 303 study should complete enrollment in the second quarter of 2008, with results expected by the end of 2008. NicOx now anticipates the filing of a New Drug Application (NDA) for naproxcinod with the US Food and Drug Administration (FDA) in mid-2009.

"The 302 study is the largest and longest duration trial in our program for naproxcinod and our clinical team has proved its effectiveness in successfully recruiting the targeted number of patients in-line with projected timelines," said Pascal Pfister, Chief Scientific Officer of NicOx. "The 302 study will p
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., , BILLERICA, Mass., Dec. 4 /PRNewswi...y-owned subsidiary of Volcano Corporation (Nasdaq:...and successful testing of a novel integrated light...ves this proprietary optical engine design raises ... limitations of laser-based designs for swept sour...
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 /PRNewswire-First...r the "Company") (OTC Bulletin Board: NWBO) announ...has allowed its patent application on a system for...re of the Company,s DCVax® therapeutic cancer... key to the very high concentration of dendritic c...
(Date:12/3/2009)..., , ALISO VIEJO, Calif. and STATE COLLEG...SoftGenetics today announced the signing of an agr... services using SoftGenetics, NextGENe software fo... Ambry. ,, (Logo: http://www.newscom.com/cg...sheidt PhD, Ambry,s CSO said, "Our team at Ambry h...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 1Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 2Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 4Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 1Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 2Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 3Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 1Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 2Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 3
...s of Disease Activity as Measured,by MRI and Relap...ech, Inc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasda... II clinical study of Rituxan®,(rituximab) in ...is,(RRMS) were presented today at the American Aca...ituxan is a therapeutic antibody,that targets and ...
... reduced by 40 percent compared,to delayed treatme...lthCare,Pharmaceuticals announced today new data, ...on(R) (interferon beta-1b) treatment in,patients w... (MS),can significantly reduce the risk of permane...nded Disability Status Scale,(EDSS) by 40 percent(...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 2First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 3First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 4
(Date:12/4/2009)... While Congress debates ...re costs, Leapfrog,s purchaser members point to 45... the best quality care in the nation while attaini...rban, eight children,s and three rural hospitals h...on results from The Leapfrog Hospital Survey. ,...
(Date:12/4/2009)... study shows that muscle cells grown in the lab ca...roperly. The work, performed in dogs and rats, mig...such as gastric reflux and fecal incontinence. , ...rs, which are the bands of muscle that separate th...s in these areas can cause gastrointestinal esopha...
(Date:12/4/2009)...s are recruited annually to participate in clinica...rch Protection (AHRP), and most will be compensate...utions view payments to volunteers as compensation...tential risks related to participating in the expe...ve a very different view of clinical trial compens...
(Date:12/4/2009)...one immediately or 3 weeks later, study shows , ...g of surgical repair or reconstruction of multiple...come, a new study has found. , Multiple-ligamen...tions that can occur in high-impact car crashes or...rgery to repair these injuries hasn,t been definit...
(Date:12/4/2009)...wire/ -- Substantial progress has been made over t...lity to diagnose and treat epilepsy and its compli... has not reached most of the 50 million people aro...million people in the United States who have the d....D., president of the American Epilepsy Society (A...
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
..., yet 2 million people die of cardiovascular disea...e is now affecting younger generations due to unhe...ture deaths. Recent studies have highlighted the ... to develop national strategies to combat heart di...
...M) has,focused its culinary expertise this time to...u salivating for more. Italians have known for cen...age as natural as spaghetti and,meatballs. Now Twi...ew., (Photo: http://www.newscom.com/cgi-bin/prnh...
...lutions, Inc.,(Accuro) (http://www.accurohealth.c...cle management market with the acquisition of TPMS...rovides contract management services to a,strong c...MS,personnel to continue to provide the excellent ...
... Hyperion,Therapeutics, Inc., a privately held bio...S. Zoth has been elected to the company,s Board of...e President and Chief,Financial Officer of MedImmu...n discussing her appointment, Ms. Zoth commented, ...
...ncrease the bronchoscopy market, to approximately...earch Group, WALT...,Research Group,s US Markets for ENT & Bronchoscop... to $180 million by 2012., To date, the majority ...
...ific Corporation (NYSE: BSX ) today announced the...ounsel. Pratt is a nationally known,attorney speci...ation. He,will hold the title of "Executive Vice P...cer Jim Tobin. He plans to join,the Company May 1s...
Other Medicine News:Health News:Joining efforts to tackle heart disease 2Health News:Joining efforts to tackle heart disease 3Health News:New Twin Hens Beef Pot Pies with Organic Cornmeal Now Provide The Brand's Famous Artisan Comfort Food for Gluten-free Connoisseurs 2Health News:Hyperion Therapeutics Elects Lota Zoth to Board of Directors 2Health News:Interventional Pulmonology Creeping into Bronchoscopy Market 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 3
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: